Nektar Therapeutics NKTR Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nektar Therapeutics's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nektar Therapeutics's retained earnings?
- Nektar Therapeutics (NKTR) reported retained earnings of -$3.81B in Q1 2026.
- How has Nektar Therapeutics's retained earnings changed year-over-year?
- Nektar Therapeutics's retained earnings decreased by 4.3% year-over-year, from -$3.65B to -$3.81B.
- What is the long-term trend for Nektar Therapeutics's retained earnings?
- Over 5 years (2020 to 2025), Nektar Therapeutics's retained earnings has grown at a 10.2% compound annual growth rate (CAGR), from -$2.31B to -$3.76B.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.